Pounce™ Thrombectomy System First-in-Human Data Show 100 Percent Technical Success in Early Cases
Surmodics, Inc. (NASDAQ: SRDX) announced the successful results of its Pounce™ Thrombectomy System in 20 First-in-Human procedures, achieving 100% technical success. The procedures, presented by Dr. Gary Ansel in London, showed that 19 of 20 patients did not require thrombolytics. The average procedure lasted 79.6 minutes, targeting a range of clot types, predominantly in the superficial femoral and popliteal arteries. This device aims to provide a non-surgical solution for peripheral artery disease, potentially revolutionizing treatment options.
- 100% technical success in 20 First-in-Human procedures.
- 19 of 20 patients avoided the use of thrombolytics.
- Average procedure time of 79.6 minutes.
- Device designed to address unmet clinical needs in treating PAD.
- None.
Thrombolytics in target lesion were not used for 19 of 20 patients treated with next-generation mechanical arterial thrombectomy device
Technical success was defined as the removal of clot to restore blood flow without the use of an additional adjunct thrombectomy device. Ansel, the inventor of the Pounce Thrombectomy System and a consultant for
“The Pounce™ Thrombectomy System demonstrated technical success in these early clinical cases, showing an ability to quickly deal with a wide range of clot from soft to organized, including emboli in the peripheral arterial vasculature,” said Ansel. “This fully mechanical thrombectomy device has no power unit or other capital equipment requirement, making it easy to use and efficient for physicians to treat patients with complex peripheral artery disease (PAD).”
Average procedure time in the FIH cases was 79.6 minutes and the average lesion length measured 109 mm (range 5-300 mm). Clinical presentation time ranged from one hour to eight months, with 30 percent of cases involving acute on chronic clot. Chronic clot (25 percent), acute clot (25 percent) and subacute (15 percent) was also removed. Five percent of cases did not indicate clot classification. The superficial femoral artery was the most common vessel treated (50 percent) while 40 percent of the cases involved the popliteal artery.
“I appreciate the ease of use, the avoidance of thrombolytic therapy, and the ability to rapidly resolve limb ischemia,” said Dr.
The intuitive ‘grab and go’, non-aspiration, mechanical thrombectomy solution empowers physicians to strike quickly to capture and remove clot from the peripheral vasculature without requiring external capital equipment for operation. The Pounce Thrombectomy System is intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature.
“The Pounce Thrombectomy System has the potential to revolutionize the treatment algorithm for arterial thrombectomy,” said
The Pounce Thrombectomy device is comprised of three components: a 5 Fr delivery catheter, a basket wire, and a funnel catheter. The basket wire is delivered distal to the location of the thrombus, deploying two nitinol self-expanding baskets. The baskets capture the clot and are retracted into a nitinol collection funnel. With the clot entrained, the system is withdrawn into a minimum 7 Fr guide sheath through which the clot is withdrawn and removed from the body.
For more information on the Pounce Thrombectomy System, visit www.pouncesystem.com.
About Peripheral Artery Disease (PAD)
Worldwide, over 200 million people have PAD1, a serious and underdiagnosed circulatory condition caused by build-up of arterial plaque, most commonly in the legs. Twelve to 20 percent of Americans over 60 years old have PAD2, which increases risk of coronary artery disease, heart attack and stroke, and can impair the ability to walk. If left untreated, PAD can lead to gangrene and limb amputation.3 The 5-year mortality rate after nontraumatic major amputations of the lower extremity is estimated to range from
About
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about the potential of the Pounce Thrombectomy System and the company’s growth strategy, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
References:
1. Fowkes FG, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.
2.
3.
4. Thorud JC, Plemmons B, et al. Mortality After Nontraumatic Major Amputation Among Patients With Diabetes and Peripheral Vascular Disease: A Systematic Review. J Foot Ankle Surg. 2016 May-June; 55(3):591-9.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005288/en/
ir@surmodics.com
Source:
FAQ
What were the results of Surmodics' Pounce Thrombectomy System First-in-Human procedures?
How long did the procedures using the Pounce Thrombectomy System take?
What medical condition does the Pounce Thrombectomy System target?
Who presented the First-in-Human data for the Pounce Thrombectomy System?